Prescient Therapeutics Ltd (PTX) - Total Assets
Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) holds total assets worth AU$18.48 Million AUD (≈ $13.08 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PTX net assets for net asset value and shareholders' equity analysis.
Prescient Therapeutics Ltd - Total Assets Trend (1989–2025)
This chart illustrates how Prescient Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Prescient Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Prescient Therapeutics Ltd's total assets of AU$18.48 Million consist of 88.6% current assets and 11.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 47.4% |
| Accounts Receivable | AU$264.30K | 1.8% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$7.40K | 0.1% |
| Intangible Assets | AU$1.65 Million | 11.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1989–2025)
This chart illustrates how Prescient Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PTX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prescient Therapeutics Ltd's current assets represent 88.6% of total assets in 2025, an increase from 29.0% in 1989.
- Cash Position: Cash and equivalents constituted 47.4% of total assets in 2025, up from 1.1% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 34.0% in 1989.
- Asset Diversification: The largest asset category is intangible assets at 11.3% of total assets.
Prescient Therapeutics Ltd Competitors by Total Assets
Key competitors of Prescient Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Prescient Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.95 | 15.97 | 80.10 |
| Quick Ratio | 12.95 | 15.97 | 80.10 |
| Cash Ratio | 7.62 | 1.07 | 0.00 |
| Working Capital | AU$15.28 Million | AU$13.99 Million | AU$19.02 Million |
Prescient Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Prescient Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.22 |
| Latest Market Cap to Assets Ratio | 2.76 |
| Asset Growth Rate (YoY) | -28.6% |
| Total Assets | AU$14.56 Million |
| Market Capitalization | $40.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Prescient Therapeutics Ltd's assets at a significant premium (2.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Prescient Therapeutics Ltd's assets decreased by 28.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prescient Therapeutics Ltd (1989–2025)
The table below shows the annual total assets of Prescient Therapeutics Ltd from 1989 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$14.56 Million ≈ $10.30 Million |
-28.59% |
| 2024-06-30 | AU$20.39 Million ≈ $14.43 Million |
-27.45% |
| 2023-06-30 | AU$28.11 Million ≈ $19.89 Million |
+59.54% |
| 2022-06-30 | AU$17.62 Million ≈ $12.47 Million |
-15.97% |
| 2021-06-30 | AU$20.97 Million ≈ $14.84 Million |
+73.68% |
| 2020-06-30 | AU$12.07 Million ≈ $8.54 Million |
-19.56% |
| 2019-06-30 | AU$15.01 Million ≈ $10.62 Million |
+50.21% |
| 2018-06-30 | AU$9.99 Million ≈ $7.07 Million |
-18.31% |
| 2017-06-30 | AU$12.23 Million ≈ $8.65 Million |
-11.60% |
| 2016-06-30 | AU$13.84 Million ≈ $9.79 Million |
+182.83% |
| 2015-06-30 | AU$4.89 Million ≈ $3.46 Million |
-7.35% |
| 2014-06-30 | AU$5.28 Million ≈ $3.74 Million |
+8439.91% |
| 2012-06-30 | AU$61.82K ≈ $43.74K |
-91.19% |
| 2011-06-30 | AU$701.86K ≈ $496.61K |
-55.23% |
| 2010-06-30 | AU$1.57 Million ≈ $1.11 Million |
+32.66% |
| 2009-06-30 | AU$1.18 Million ≈ $836.11K |
-32.49% |
| 2008-06-30 | AU$1.75 Million ≈ $1.24 Million |
-46.04% |
| 2007-06-30 | AU$3.24 Million ≈ $2.30 Million |
-12.50% |
| 2006-06-30 | AU$3.71 Million ≈ $2.62 Million |
-11.36% |
| 2005-06-30 | AU$4.18 Million ≈ $2.96 Million |
+0.84% |
| 2004-06-30 | AU$4.15 Million ≈ $2.94 Million |
+153.92% |
| 2003-06-30 | AU$1.63 Million ≈ $1.16 Million |
-14.22% |
| 2002-06-30 | AU$1.90 Million ≈ $1.35 Million |
-55.53% |
| 2001-06-30 | AU$4.28 Million ≈ $3.03 Million |
+209.37% |
| 2000-06-30 | AU$1.38 Million ≈ $979.38K |
-50.53% |
| 1999-06-30 | AU$2.80 Million ≈ $1.98 Million |
+126.53% |
| 1998-06-30 | AU$1.24 Million ≈ $873.87K |
+663.49% |
| 1997-06-30 | AU$161.76K ≈ $114.46K |
+569.66% |
| 1996-06-30 | AU$24.16K ≈ $17.09K |
-98.93% |
| 1995-06-30 | AU$2.25 Million ≈ $1.59 Million |
-61.89% |
| 1994-06-30 | AU$5.90 Million ≈ $4.18 Million |
+6.34% |
| 1993-06-30 | AU$5.55 Million ≈ $3.93 Million |
-18.95% |
| 1992-06-30 | AU$6.85 Million ≈ $4.84 Million |
-3.36% |
| 1991-06-30 | AU$7.08 Million ≈ $5.01 Million |
-1.35% |
| 1990-06-30 | AU$7.18 Million ≈ $5.08 Million |
+9.43% |
| 1989-06-30 | AU$6.56 Million ≈ $4.64 Million |
-- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more